Ilomedin (Iloprost Trometamol)

Iloprost trometamol mimics the natural prostacyclin molecule by binding to IP receptors on vascular smooth‑muscle cells. Activation of these receptors raises intracellular cyclic AMP, causing the blood vessels to relax (vasodilation) and inhibiting platelet aggregation, which together improve blood flow in the pulmonary circulation and skin microvasculature.

The dosing regimen for Ilomedin is individualized and determined by the prescribing physician based on the patient’s clinical condition, response, and tolerance. Healthcare professionals adjust the infusion rate and duration to achieve the desired therapeutic effect while monitoring safety parameters.

Safety data for Ilomedin during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Ilomedin (iloprost trometamol) is a short‑acting prostacyclin analogue administered intravenously, offering rapid titration and reversible effects. Compared with longer‑acting agents such as epoprostenol or treprostinil, iloprost allows more flexible dosing schedules but may require more frequent infusions. Choice of therapy depends on patient preference, disease severity, and logistical considerations.

Ilomedin must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect the product for any particulate matter or discoloration and follow aseptic techniques for preparation and administration.

Ilomedin is supplied as a sterile injectable solution for intravenous infusion. It is administered through a controlled infusion pump or syringe driver under the supervision of qualified healthcare personnel. The infusion rate is gradually increased during the initial titration phase to achieve the target therapeutic response while monitoring vital signs.

The most serious adverse events associated with Ilomedin include severe hypotension, which can lead to syncope or organ hypoperfusion, pulmonary edema, and significant bleeding, especially when used with anticoagulants. Prompt recognition of these signs and immediate medical intervention are essential to mitigate complications.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation. It should also be avoided in individuals with active uncontrolled bleeding, severe hypotension, or those receiving other prostacyclin analogues without careful medical supervision.